ArticleBMC medicine2026
Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCirculating tumor DNA (ctDNA) profiling offers a noninvasive approach to monitor minimal residual disease (MRD) and clonal evolution in diffuse large B-cell lymphoma (DLBCL).
methodsIn this study, we analyzed 164 newly diagnosed DLBCL patients from the First Affiliated Hospital of Nanjing Medical University undergoing R-CHOP-like therapy. Tissue and serial plasma samples were sequenced using a 475-gene lymphoma-specific panel.
resultsWe defined end-of-treatment MRD (EOT-MRD) positivity based on detectable tissue-informed variants or published driver mutations, which identified 37.2% (61/164) of patients as EOT-MRD( +). EOT-MRD status significantly predicted progression-free and overall survival, complementing both International Prognostic Index (IPI) and positron emission tomography-computed tomography response assessment. Integration of EOT-MRD with IPI into a composite "IPI-M" model improved risk stratification. CtDNA dynamics revealed that 77.1% (37/48) of patients acquired new gene alterations (GAs) at progression, of which most were enriched in cell cycle regulation, p53 pathway, PI3K/AKT signaling pathway, and epigenetic regulation. In addition, primary refractory patients exhibited a higher proportion of shared mutations from baseline to progression, while relapsed patients gained more emergent mutations at progression. Different genetic subtypes manifest divergent progression and distinct evolutionary patterns. TP53-disrupted subtype drove primary refractoriness via persistence of TP53 mutation, MCD subtype was prone to relapse despite high remission rate with frequent baseline mutation clearance and propensity for branched evolution, and BN2 showed mixed refractoriness and relapse with predominance of shared alterations.
conclusionsOur findings underscore the dual utility of ctDNA in enhancing prognostic stratification and elucidating subtype-specific evolutionary dynamics, supporting personalized treatment strategies in DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.